[1]Moshe SL, Perucca E, Ryvlin P, et al. Epilepsy: new advances[J] . Lancet, 2015, 385(9971):884-898.
[2]Schmidt D, Schachter SC. Drug treatment of epilepsy in adults[J]. BMJ, 2014, 348:g254.
[3]Lian XY, Zhang ZZ, Stringer JL. Anticonvulsant activity of ginseng on seizures induced by chemical convulsants[J]. Epilepsia, 2005, 46(1):15-22.
[4]Yang XD, Yang YY, Ouyang DS, et al. A review of biotransformation and pharmacology of ginsenoside compound K[J]. Fitoterapia, 2015, 100:208-220.
[5]Park JS, Shin JA, Jung JS, et al. Anti-inflammatory mechanism of compound K in activated microglia and its neuroprotective effect on experimental stroke in mice [J]. J Pharmacol Exp Ther, 2012, 341(1):59-67.
[6]Bae MY, Cho JH, Choi IS, et al. Compound K, a metabolite of ginsenosides, facilitates spontaneous GABA release onto CA3 pyramidal neurons[J]. J Neurochem, 2010,114 (4):1085-1096.
[7]Jang S, Ryu JH, Kim DH, et al. Changes of [3H]MK-801, [3H]muscimol and [3H]flunitrazepam binding in rat brain by the prolonged ventricular infusion of transformed ginsenosides[J]. Neurochem Res, 2004,29(12):2257-2266.
[8]Inoue O, Sugiyama E, Hasebe N, et al. Methyl ethyl ketone bloC-Ks status epilepticus induced by lithium-pilocarpine in rats[J]. Br J Pharmacol, 2009,158(3):872-878.
[9]Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure[J]. Electroencephalogr Clin Neurophysiol,1972, 32(3):281-294.
[10]于雷,李成龙,于珊珊. 人参皂苷C-K的研究进展[J]. 生物技术通报,2013(01):31-35.
[11]Lee J, Lee E, Kim D, et al. Studies on absorption, distribution and metabolism of ginseng in humans after oral administration[J]. J Ethnopharmacol, 2009,122(1):143-148.
[12]Lee JH, Kim SR, Bae CS, et al. Protective effect of ginsenosides, active ingredients of Panax ginseng, on kainic acid-induced neurotoxicity in rat hippocampus[J]. Neurosci Lett,2002, 325(2):129-133.
[13]Kim S, Rhim H. Ginsenosides inhibit NMDA receptor-mediated epileptic discharges in cultured hippocampal neurons[J]. Arch Pharm Res, 2004, 27(5):524-530.
[14]Shin EJ, Koh YH, Kim A Y, et al. Ginsenosides attenuate kainic acid-induced synaptosomal oxidative stress via stimulation of adenosine A(2A) receptors in rat hippocampus[J]. Behav Brain Res, 2009,197(1):239-245.
[15]Tohda C, Matsumoto N, Zou K, et al. Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, a metabolite of protopanaxadiol-type saponins[J]. Neuropsychopharmacology, 2004, 29(5):860-868.
[16]Zhang H, Li Z, Zhou Z, et al. Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20(S)-protopanaxadiol in mice models of despair[J]. Pharmacol Biochem Behav, 2016, 140:17-26.
[17]Moon J, Park HK, Chu K, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population[J]. Epilepsia, 2015, 56(10):e161-e167.
[18]Ordonez L, Salgueiro E, Jimeno FJ, et al. Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs[J]. Eur Rev Med Pharmacol Sci,2015,19(14):2732-2737.
[19]Kim JR, Choi J, Kim J, et al. 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol-fortified ginseng extract attenuates the development of atopic dermatitis-like symptoms in NC/Nga mice[J]. J Ethnopharmacol, 2014, 151(1):365-371.
[20]Shin YW, Bae EA, Kim SS, et al. Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis[J]. Int Immunopharmacol, 2005, 5(7-8):1183-1191. |